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Abstract
Purpose: microRNAs have emerged as key regulators of gene expression, and their altered expression has been associated
with tumorigenesis and tumor progression. Thus, microRNAs have potential as both cancer biomarkers and/or potential
novel therapeutic targets. Although accumulating evidence suggests the role of aberrant microRNA expression in
endometrial carcinogenesis, there are still limited data available about the prognostic significance of microRNAs in
endometrial cancer. The goal of this study is to investigate the prognostic value of selected key microRNAs in endometrial
cancer by the analysis of archival formalin-fixed paraffin-embedded tissues.
Experimental Design: Total RNAs were extracted from 48 paired normal and endometrial tumor specimens using Trizol
based approach. The expression of miR-26a, let-7g, miR-21, miR-181b, miR-200c, miR-192, miR-215, miR-200c, and miR-205
were quantified by real time qRT-PCR expression analysis. Targets of the differentially expressed miRNAs were quantified
using immunohistochemistry. Statistical analysis was performed by GraphPad Prism 5.0.
Results: The expression levels of miR-200c (P,0.0001) and miR-205 (P,0.0001) were significantly increased in endometrial
tumors compared to normal tissues. Kaplan-Meier survival analysis revealed that high levels of miR-205 expression were
associated with poor patient overall survival (hazard ratio, 0.377; Logrank test, P=0.028). Furthermore, decreased expression
of a miR-205 target PTEN was detected in endometrial cancer tissues compared to normal tissues.
Conclusion: miR-205 holds a unique potential as a prognostic biomarker in endometrial cancer.
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Introduction
Endometrial cancer is the most common malignancy of the
female genital tract in the United States [1]. The overall five-year
survival of endometrial cancer is approximately 80% among all
stages. Although it has a relatively low rate of mortality compared
to other gynecologic cancers, certain histologic types are highly
invasive, frequently metastatic and have poor survival rates. The
most dominant subtype, endometrioid endometrial cancer (EEC)
accounts for approximately 80% of the cases. Surgery is typically
curative with the majority of these cases diagnosed at an early
stage. In contrast, patients with advanced stage or nonendome-
trioid endometrial cancers tend to display more aggressive
characteristics and have a much less favorable prognosis [2].
Although the morphological alterations reflect important insights
into endometrial cancer, there is an urgent need for highly
sensitive and specific molecular prognostic biomarkers to better
predict the outcome of endometrial cancer, especially in more
than 25% of the endometrioid endometrial tumors with high risk
to develop more aggressive diseases.
Recently, molecular studies have identified microsatellite
instability and mutations in PTEN, K-ras, beta-catenin, p53,
HER-2/neu, p16 and E-cadherin genes in cases of endometrial
cancer [3]. Particularly, the incidence of PTEN mutations has
been reported to be the highest among other genetic alterations,
existing in 34–55% of endometrial cancers [4–6]. PTEN is an
important tumor suppressor in endometrial cancer, and the
identification of these molecular rearrangements can aid in better
understanding of endometrial cancer biology and can also lead to
the discovery of novel molecular targets for the detection,
prognosis, and therapy. Although these genetic alterations have
been described as important, they are not universally present in all
cases suggesting that epigenetic mechanisms (such as microRNAs)
may also be involved.
MicroRNAs (miRNAs) are small, non-coding RNA molecules of
19–25 nucleotides that regulate gene expression post-transcrip-
tionally through binding to the 39-untranslated region (39-UTR) of
target mRNAs, causing mRNA cleavage, translational repression,
or mRNA decay [3,7] miRNAs have been found to regulate many
critical cellular processes including apoptosis [8–11], differentia-
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expression of miRNAs is observed in most tumor types, indicating
a role in carcinogenesis and a potential as prognostic/diagnostic
biomarkers in cancer [17,18]. We reason that miRNAs may be
utilized as a better class of biomarkers due to their broad
regulatory functions. In addition, the superior stability of miRNAs
in formalin-fixed paraffin-embedded (FFPE) tissues and various
body fluids (e.g., plasma, serum) further facilitates the clinical
utility of miRNAs.
A number of recent studies have reported the expression profiles
of miRNAs in endometrial cancer [19–26]. In this study, we aimed
to investigate the prognostic value of miRNAs using archival FFPE
samples of endometrial cancer patients. We systematically
quantified the expressions of candidate miRNAs involved in
critical cellular processes such as cell cycle control, chemoresis-
tance, cell death and EMT transition (miR-26a, let-7g, miR-21,
miR-181b, miR-192, miR-215, miR-200c, and miR-205) using
quantitative real-time PCR (qRT-PCR) analysis. These miRNAs
were chosen based on their critical target genes that are disrupted
during endometrial carcinogenesis (e.g. p53, K-ras, PTEN) [27–
32]. Our results show that the expression levels of miR-200c and
miR-205 were significantly over-expressed in endometrial cancer.
However, only the expression of miR-205 was significantly
associated with patient survival. Previous studies have identified
PTEN as one of the direct targets of miR-205 [33,34].
Considering the significance of PTEN in endometrial cancer
biology, we hypothesized that the miR-205 mediated PTEN
inhibition mechanism might have an in vivo physiologic relevance
in endometrial cancer. Indeed, our results have demonstrated that
the expression levels of miR-205 were significantly inversely
correlated with the expression levels of PTEN. As a result, our
findings suggest that miR-205 may hold a unique potential as a
biomarker for the prognosis of endometrial cancer.
Results
Expression of miRNAs in human endometrial cancer and
evaluation of their prognostic values
The clinicopathologic parameters of the 48 endometrial cancer
patients used in this study are described in Table 1. Half of the
patients had endometrioid carcinoma, and the remaining patients
were diagnosed with nonendometrioid histology (13 serous
carcinoma, 5 clear cell carcinoma, 5 malignant mixed mullerian
tumor (MMMT), and one undifferentiated carcinoma). Of these
patients, 26 cases had stage I (54%), four cases had stage II (8%), 6
cases had stage III (13%), and 12 cases had stage IV (25%) of the
disease. To investigate the clinical significance of the selected
miRNAs in these endometrial cancer patients, we quantified their
expression levels from 48 paired archival tumor and normal FFPE
tissue specimens using real time qRT-PCR analysis. Of the
miRNAs tested, there was no significant difference in the
expression levels of miR-26a, let-7g, miR-21, miR-181b, miR-
192, and miR-215 between tumor tissues and corresponding
normal samples (P=0.742; P=0.91; P=0.641; P=0.313;
P=0.106; P=0.336, respectively) (Figure 1A–F). In contrast, the
expression of both miR-200c (P,0.0001; Figure 1G) and miR-205
(P,0.0001; Figure 1H) were significantly up-regulated in
endometrial cancer specimens compared to adjacent normal
tissues. To further analyze the significance of miR-200c and miR-
205 in terms of clinical prognosis, Kaplan-Meier survival analysis
was performed, using patient overall survival (Figure 2). Our
results indicated that expression levels of miR-205 were signifi-
cantly associated with patient survival. Patients with low levels
(cut-off 15-fold of miR-205) tended to have better survival than
patients with high levels of miR-205 (hazar ratio, 0.377; Logrank
test, P=0.028) (Figure 2B). This supports the notion that elevated
levels of miR-205 in tumor tissues could lead to worse survival
rates in endometrial cancer patients. However, expression levels of
miR-200c were not associated with patient survival (P=0.576;
Figure 2A).
Correlation of miR-205 and PTEN expression in
endometrial cancer patients
It has been reported that miR-205 targets a critical tumor
suppressor gene PTEN [33,34], which is frequently mutated or
deleted in endometrial cancer [4–6]. However, genetic alterations
cannot account for all PTEN protein loss observed in endometrial
carcinomas, strongly suggesting the involvement of a post-
transcriptional regulation in PTEN expression [35,36]. Since the
expression levels of miR-205 were elevated in tumor tissues, we
reasoned that enhanced inhibition of PTEN by miR-205 might be
a physiologically relevant mechanism during endometrial carci-
nogenesis. In order to investigate an in vivo relationship between
miR-205 and PTEN protein expression, we constructed tissue
microarrays (TMAs) from archival FFPE tissue specimens and
performed immunohistochemistry with PTEN 6H2.1 antibody on
sectioned TMAs. Our results indicate that PTEN protein
expression was decreased in endometrial cancer compared to
Table 1. Characteristics of endometrial cancer patients used
for the study.
Clinicopathologic Parameters (n=48) n
Pathology
Endometrioid carcinoma 24
Serous carcinoma 13
Clear cell carcinoma 5
Malignant mixed mullerian tumor (MMMT) 5
Undifferentiated carcinoma 1
FIGO Stage
Endometrioid carcinoma
Stage I 18
Stage II 2
Stage III 1
Stage IV 3
Serous carcinoma
Stage I 4
Stage II 2
Stage III 2
Stage IV 5
Clear cell carcinoma
Stage I 3
Stage IV 2
Malignant mixed mullerian tumor (MMMT)
Stage I 1
Stage III 3
Stage IV 1
Undifferentiated carcinoma
Stage IV 1
doi:10.1371/journal.pone.0035158.t001
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PTEN was significantly lower in tumor tissues (median score 85)
compared to normal tissues (median score 132) (P=0.0058).
Figure 3 (B–E) shows examples of PTEN staining in normal
endometrium (3B), endometrioid carcinoma (3C), serous carcino-
ma (3D), and clear cell carcinoma (3E).
Figure 2. Relationship between miRNA expression and survival in endometrial cancer patients. Kaplan-Meier overall survival curves were
plotted based on miRNA expression. (A) miR- 200c expression (P=0.576, Logrank test). (B) miR-205 expression (P=0.028, Logrank test).
doi:10.1371/journal.pone.0035158.g002
Figure 1. miRNA expression in normal and endometrial cancer tissue specimens. Relative quantification of miRNAs was expressed as
normalized with an internal control RNU6B gene. (A) miR-26a expression (P=0.742). (B) let-7g expression (p=0.91). (C) miR-21 expression (P=0.641).
(D) miR-181b expression (P=0.313). (E) miR-192 expression (P=0.106). (F) miR-215 expression (P=0.336). (G) miR-200c expression (P,0.0001). (H)
miR-205 expression (P,0.0001). Statistical significance was calculated by a paired Student’s t-test.
doi:10.1371/journal.pone.0035158.g001
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and PTEN expression, we performed a non-parametric spearman
correlation analysis by using the cases that have both miR-205 and
PTEN protein quantification data. Our results indicate the
presence of an inverse correlation in 69% of the cases (spearman
correlation coefficient=20.502, P=0.034) (Figure 4A). Figure 4B
and Figure 4C show examples of PTEN staining accompanied by
miR-205 expression levels in individual cases. Figure 4B demon-
strates an undifferentiated carcinoma with high PTEN staining
and only a slight up-regulation in miR-205 expression between
tumor and adjacent normal tissue (,1.25 fold). Figure 4C
demonstrates a clear cell carcinoma with very low PTEN staining
and ,350 fold up-regulation in miR-205 expression between
tumor and adjacent normal tissue.
Finally, to support our hypothesis that decreased PTEN protein
expression is mediated by a post-transcriptional control, we
quantified PTEN mRNA levels using real-time qRT-PCR. Our
results indicate that PTEN mRNA expression levels in endome-
trial cancer specimens showed no difference when compared to
adjacent normal tissues (Figure 5). These results suggest that the
lack of correlation of PTEN mRNA with the loss of PTEN protein
in endometrial cancer was likely due to a post-transcriptionally
regulated mechanism.
Discussion
In this study, we identified significantly over-expressed miR-
200c and miR-205 in endometrial cancer compared to normal
endometrial tissue (Figure 1). This finding is consistent with many
other studies reporting elevated levels of these two miRNAs in
different types of endometrial cancer [19–24,26]. Therefore, we
suggest that the over-expression signature of these miRNAs in
endometrial cancer is not specific for histologic type. Chung et al.
reported that the aberrant expression of miR-205 was correlated
with advanced stage in endometrial cancer [22]. However, our
results showed that miR-205 expression was not related to the
stage disease or tumor type (Figure S1). We discovered that miR-
205 expression was significantly associated with overall patient
survival such that patients with higher levels of miR-205 tend to
have a worse survival phenotype (Figure 2). Our results support a
notion that miR-205 may have potential as a biomarker for the
negative prognosis of endometrial cancer and therapeutic
approaches targeting elevated levels of miR-205 should be
explored as a novel approach to improve clinical outcomes.
The miR-200 family and miR-205 have also been reported to
be dysregulated in other types of cancer. The miR-200 family has
been reported to be up-regulated in ovarian cancer and
Figure 3. PTEN protein expression in endometrial cancer patients. (A) Scatter plot of immunostaining scores for PTEN in normal
endometrium and endometrial cancer calculated by quantifying the staining intensity using ImageJ software. Bars represent the median for each
category (normal median=85, tumor median=132). (B–E) PTEN protein expression is detected in normal endometrium (B), endometrioid carcinoma
(C), serous carcinoma (D), and clear cell carcinoma (E) as detected by immunohistochemistry.
doi:10.1371/journal.pone.0035158.g003
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lar carcinoma, breast cancer and renal cell carcinoma [40–42]. By
contrast, miR-205 has been reported to be up-regulated in
ovarian, bladder, and breast carcinomas [37,43,44], but down-
regulated in prostate and esophageal cancers [45,46]. These
different expression patterns in some types of cancer may reflect
the presence of tumor type-specific mechanisms that are mediated
by regulatory miRNAs. The most well-known function of the miR-
200 family and miR-205 is their ability to regulate the expression
of E-cadherin transcriptional repressors ZEB1 (also known as
dEF1) and SIP1 (also known as ZEB2), factors important for
epithelial mesenchymal transition (EMT) and tumor metastasis
[32]. However, miR-200 family and miR-205 function as tumor
suppressors through the inhibition of EMT. Since the expression
of these miRNAs is increased in the tumor samples, we reasoned
that other proteins targeted by these miRNAs might be involved in
endometrial cancer. One of the reported targets of miR-205 is a
critical tumor suppressor gene, PTEN [33,34].
PTEN expression has been reported to be reduced in
endometrial carcinoma [4], thus it has a critical role in
endometrial cancer biology [35,36,47,48]. However, mutations/
deletions of PTEN are not the only reason for the reduced PTEN
expression. Rather, epigenetic mechanisms, such as promoter
methylation, increased PTEN protein degradation or regulation
through miRNAs are also important [49]. With this in mind, we
analyzed the expression levels of PTEN mRNA and protein in
endometrial cancer patients. We have shown that, although there
was no change in the expression of PTEN mRNA, the expression
of PTEN protein was decreased in tumor tissues compared to
Figure 4. Correlation between miR-205 and PTEN expression in endometrial cancer patients. (A) Correlation of miR-205 and PTEN
expression was analyzed by two-tailed Spearman nonparametric correlation test (P=0.034, Spearman correlation coefficient=20.502). PTEN protein
expression accompanied by miR-205 expression (in triplicate) is illustrated in individual cases; undifferentiated carcinoma (B), and clear cell carcinoma
(C).
doi:10.1371/journal.pone.0035158.g004
Figure 5. PTEN mRNA expression in endometrial cancer
patients. Relative quantification of PTEN mRNA was expressed as
normalized with an internal control b-actin gene (p=0.31). Statistical
significance was calculated by a paired Student’s t-test.
doi:10.1371/journal.pone.0035158.g005
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transcriptional regulation of PTEN, possibly mediated by
miRNAs, is valid. Together with the reports that PTEN is the
direct target of miR-205, our results support the potential role of
miR-205 in regulating PTEN in endometrial cancer.
In general, a decrease in PTEN expression is associated with
endometriod carcinoma and may be a useful biomarker to
distinguish endometrioid carcinoma from serous carcinoma [4].
However, other studies have reported no significant difference in
PTEN expression, suggesting that PTEN may not always be useful
to distinguish these tumor subtypes [50,51]. Therefore, the clinical
utility of PTEN as a biomarker remains to be determined. We
reason that miR-205 may be a superior biomarker than PTEN
due to its broad impact on multiple targets and pathways.
In summary, our results indicate that the expression of miR-205
and PTEN are inversely correlated in endometrial cancer patients,
implying the physiologic significance of the miR-205 mediated
PTEN inhibition mechanism in endometrial cancer biology. More
importantly, the expression of miR-205 is associated with
endometrial cancer patient survival. Thus, we reason that miR-
205 may regulate PTEN and other protein expression in the
pathogenesis of endometrial cancer. Future studies are clearly
needed to fully validate the clinical utility of miR-205 as prognostic
biomarker with multicenter large endometrial cancer patient
cohorts.
Materials and Methods
Ethics
Clinical sample cohort used for this study was approved by the
Institution Review Board of Stony Brook University Medical
Center. Written informed consent was received from all
participants involved in the study.
Patients and Samples
Approval from the Institution Review Board was obtained for
both the collection of tissues and the use of archival formalin-fixed
paraffin embedded (FFPE) tissue blocks. For RNA extraction,
tumor samples and the adjacent normal tissues were obtained
from 48 endometrial cancer patients who underwent hysterectomy
at Stony Brook University Hospital, Stony Brook, NY. The
characteristics of these patients are shown in Table 1. For
immunohistochemistry, tumor tissues were obtained from 47
endometrial cancer patients and non-pathologic endometrial
tissues as normal controls were obtained from five non-
endometrial cancer patients. Paraffin blocks containing formalin-
fixed specimens of the tissues (FFPE) were acquired from the
archival collections of the Department of Pathology and used for
subsequent analyses. The specimens were selected from 1995 to
2010 with up to 15 years clinical follow up information.
Tissue Microarrays (TMAs)
Tissue microarrays were prepared from FFPE blocks of
hysterectomy specimens. Hematoxylin and Eosin stained sections
from all cases were carefully reviewed. For each case, areas of
endometrial cancer and normal endometrium were designated.
Using the Advanced Tissue Arrayer (Model: ATA-100, Millipore,
Billerica, MA, USA), with a 1.5 mm diameter needle, three cores
were extracted from the area of tumor and three cores were
removed from the benign endometrium for each case. The cores
were embedded into a paraffin tissue microarray block in
predetermined positions, with up to 60 cores in each tissue
microarray and two additional cores placed to designate the
orientation of the block.
Immunohistochemistry (IHC) Analysis of PTEN Expression
TMAs were sectioned at 5 mm and the sections were heat
immobilized on glass slides at 60uC overnight. After deparaffiniza-
tion, antigen retrieval was performed in a citrate buffer [20 mmol/
L (pH=6)] at 120uC for 10 minutes followed by 3% hydrogen
peroxide for five minutes. Staining was applied to FFPE tissues by
using an avidin-biotin (ABC) method (Vector Laboratories,
Burlingame, CA). Sections were incubated for one hour with a
mouse monoclonal PTEN antibody, PTEN 6H2.1 (Cascade
Biosciences, Winchester, MA) at a dilution of 1:300. Monoclonal
mouse IgG (BD Biosciences, Franklin Lakes, NJ, USA) was used as
an isotype–negative control. PTEN staining was visualized using 3,
39-diaminobenzidine (Dako, Carpinteria, CA), and sections were
counterstained with dilute hematoxylin, dehydrated, and cover-
slipped for bright-field microscopy. Staining for IHC was
quantified by averaging intensity from three cores of each case
(ImageJ software (http://rsb.info.nih.gov/ij/)).
RNA Isolation
Using archival FFPE tissues, separate areas of tumor and
normal endometrium were identified using the corresponding
Hematoxylin and Eosin stained sections and cores measuring
1.5 mm in diameter and 2 mm in length (approximately 0.005 g)
were extracted. Subsequently, the samples were deparaffinized,
hydrated, digested with proteinase K, and ultimately, total RNAs
were isolated using TRIZOL reagent (Invitrogen, Carlsbad CA,
USA).
Real time qRT-PCR Analysis of miRNA Expression
The miR-26a, let-7g, miR-21, miR-181b, miR-192, miR-215,
miR-200c, and miR-205 specific primers and the internal control
RNU6B gene were purchased from Ambion (Applied Biosystems,
CA, USA). cDNA synthesis was performed by the High Capacity
cDNA Synthesis Kit (Applied Biosystems, CA, USA) with miRNA
specific primers. Real-time quantitative RT-PCR (qRT-PCR) was
carried out on an Applied Biosystems 7500 Real-time system (ABI
7500HT instrument) with miRNA specific primers by TaqMan
Gene Expression Assay.
Real time qRT-PCR Analysis of PTEN mRNA
In order to detect mRNA from FFPE tissues, cDNA synthesis
was performed by the High Capacity cDNA Synthesis Kit
(Applied Biosystems, CA, USA) with random primers. For qRT-
PCR analysis, custom designed real time PCR primers and probes
for PTEN and the internal control gene b-actin were used
(Applied Biosystems CA, USA). The primers were designed to
obtain as small amplicons as possible due to the concern about the
degradation of mRNA in FFPE tissues [52]. The sequences of
these primers/probes are listed in Table 2. qRT-PCR was carried
out on an ABI 7500HT instrument with mRNA specific primers
by TaqMan Gene Expression Assay under the following
conditions: 50uC, 2 min of reverse transcription; 95uC, 10 min;
95uC, 15 s; 60uC, 1 min for up to 40 cycles (n=3). Expression of
PTEN mRNA was normalized according to the internal b-actin
control, and the relative expression values were plotted.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
software 5.0. Gene expression DCt values of miRNAs from each
sample werecalculatedbynormalizingaccordingto internal control
RNU6B expression, and relative quantification values were plotted.
Thedifferencesbetweentumorandnormaltissueswereanalyzed by
a paired Student’s t-test. Kaplan-Meier survival curves were
miR-205 in Endometrial Cancer
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35158generated to evaluate the expression levels of miR-200c and miR-
205 with survival rate. Unpaired Student’s t-test was used to analyze
the difference in PTEN staining between tumor and normal tissues.
Statistical significance was set up to P,0.05 in each test.
Supporting Information
Figure S1 Relationship between miR-205 expression and
different stages of endometrial cancer. miR-205 expression
was expressed as normalized with an internal control RNU6B gene.
(A) One-way ANOVA test was used to analyze the association of
miR-205 expression in stage I, stage II, stage III and stage IV of
endometrialcancer.(B)Unpaired Student’st-testwasusedtoanalyze
the association of miR-205 expression in stage I&II vs stage III&IV.
(TIF)
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